Phil McEwan

6.4k total citations · 1 hit paper
205 papers, 4.5k citations indexed

About

Phil McEwan is a scholar working on Endocrinology, Diabetes and Metabolism, Epidemiology and Economics and Econometrics. According to data from OpenAlex, Phil McEwan has authored 205 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Endocrinology, Diabetes and Metabolism, 44 papers in Epidemiology and 42 papers in Economics and Econometrics. Recurrent topics in Phil McEwan's work include Diabetes Treatment and Management (62 papers), Diabetes Management and Research (45 papers) and Health Systems, Economic Evaluations, Quality of Life (39 papers). Phil McEwan is often cited by papers focused on Diabetes Treatment and Management (62 papers), Diabetes Management and Research (45 papers) and Health Systems, Economic Evaluations, Quality of Life (39 papers). Phil McEwan collaborates with scholars based in United Kingdom, United States and Sweden. Phil McEwan's co-authors include Craig J. Currie, Klas Bergenheim, Marc Evans, Louise B. Russell, Murray Krahn, A. David Paltiel, Michael Chambers, Mark S. Roberts, Adam Lloyd and Yong Yuan and has published in prestigious journals such as Circulation, PLoS ONE and Hepatology.

In The Last Decade

Phil McEwan

193 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Weight loss and risk reduction of obesity-related outcomes in 0.5 million people: evidence from a UK primary care database

2021 119 citations Phil McEwan et al. International Journal of Obesity profile →

Peers

Countries citing papers authored by Phil McEwan

Since Specialization

Citations

This map shows the geographic impact of Phil McEwan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phil McEwan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phil McEwan more than expected).

Fields of papers citing papers by Phil McEwan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Phil McEwan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Phil McEwan. The network helps show where Phil McEwan may publish in the future.

Co-authorship network of co-authors of Phil McEwan

This figure shows the co-authorship network connecting the top 25 collaborators of Phil McEwan. A scholar is included among the top collaborators of Phil McEwan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Phil McEwan. Phil McEwan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Beyond glycated haemoglobin: Modelling contemporary management of type 2 diabetes with the updated Cardiff model 2025 ·Diabetes Obesity and Metabolism ·Phil McEwan, V. Foos, Geraint Roberts, Robert L. Jenkins, Marc Evans, David C. Wheeler, Jieling Chen	1
2	The evolving burden of obesity in the US: a novel population-level system dynamics approach 2025 ·Journal of Medical Economics ·Phil McEwan, Mads Faurby, (unknown), Thomas Padgett, (unknown)	0
3	The Broader Effects of Delayed Progression to End-Stage Kidney Disease: Delaying the Inevitable or a Meaningful Change? 2024 ·Advances in Therapy ·R Correa-Rotter, David C. Wheeler, Phil McEwan	1
4	Global barriers to decision makers for prioritizing interventions for obesity 2024 ·International Journal of Obesity ·Lars Holger Ehlers, (unknown), Rasmus H. Olesen, Jens‐Christian Holm, Phil McEwan, Carel W. le Roux	0
5	The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis 2024 ·Nephrology Dialysis Transplantation ·Phil McEwan, (unknown), Jason A. Davis, Juan José García Sánchez, C. David Sjöström, Salvatore Barone, (unknown), Mario Ouwens, (unknown), Ricardo Correa-Rotter, Peter Rossing, David C. Wheeler, Hiddo J.L. Heerspink	8
6	The Population-Wide Risk-Benefit Profile of Extending the Primary COVID-19 Vaccine Course Compared with an mRNA Booster Dose Program 2022 ·Vaccines ·Tinevimbo Shiri, (unknown), Carla Talarico, Angharad R. Morgan, (unknown), Philip O. Buck, Phil McEwan, W. David Strain	7
7	Vaccinating Adolescents and Children Significantly Reduces COVID-19 Morbidity and Mortality across All Ages: A Population-Based Modeling Study Using the UK as an Example 2021 ·Vaccines ·Tinevimbo Shiri, Marc Evans, Carla Talarico, Angharad R. Morgan, (unknown), Philip O. Buck, Phil McEwan, W. David Strain	16
8	Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective 2020 ·Journal for ImmunoTherapy of Cancer ·Casey Quinn, Louis P. Garrison, (unknown), Michael B. Atkins, Gérard de Pouvourville, Kevin J. Harrington, Paolo A. Ascierto, Phil McEwan, Samuel Wagner, (unknown), (unknown)	34
9	Relationship between hypoglycaemia, body mass index and quality of life among patients with type 1 diabetes: Observations from the DEPICT clinical trial programme 2020 ·Diabetes Obesity and Metabolism ·Jason Gordon, (unknown), Hayley Bennett, (unknown), Christopher Edmonds, Phil McEwan	7
10	Retrospective Database Analysis Evaluating the Clinical Outcomes of Changing Treatment of People with Type 2 Diabetes Mellitus (T2DM) from Other DPP-4 Inhibitor Therapy to Alogliptin in a Primary Care Setting 2019 ·Diabetes Therapy ·W. David Strain, Phil McEwan, (unknown), (unknown)	3
11	Predicting atrial fibrillation in primary care using machine learning 2019 ·PLoS ONE ·Nathan R. Hill, Daniel Ayoubkhani, Phil McEwan, Daniel Sugrue, Usman Farooqui, Steven Lister, Matthew Lumley, Ameet Bakhai, Alexander T. Cohen, Mark O’Neill, David A. Clifton, Jason Gordon	90
12	Treatment choice, medication adherence and glycemic efficacy in people with type 2 diabetes: a UK clinical practice database study 2018 ·BMJ Open Diabetes Research & Care ·Jason Gordon, Phil McEwan, Iskandar Idris, Marc Evans, Jorge Puelles	40
13	Implications of Introducing Patient Heterogeneity in Cost Effectiveness Modeling 2016 ·Value in Health ·V. Foos, Phil McEwan, Mark Lamotte	1
14	The Role of Patient Level Data In Assessing Health Economic Value: A Case Study Using Edge and The Core Diabetes Model 2015 ·Value in Health ·V. Foos, Phil McEwan, Marc Evans, Päivi M. Paldánius	1
15	Epidemiology, treatment and health economics of Hepatitis C in Japan (Review) 2014 ·Kanzo ·Isao Kamae, Hiromitsu Kumada, Masahiro Kobayashi, Thomas Ward, (unknown), Yong Yuan, Anupama Kalsekar, Sachie Inoue, Ann Tang, Phil McEwan	3
16	Predicting the Frequency of Severe and Non-Severe Hypoglycaemia in Insulin Treated Type-2 Diabetes Subjects 2013 ·Value in Health ·Phil McEwan, V. Foos, David Grant, James L. Palmer, N. Varol, B. Curtis, Kristina S. Boye	3
17	Drivers Of Cost-Effectiveness In Type-2 Diabetes Mellitus 2013 ·Value in Health ·Phil McEwan, V. Foos, (unknown), Mark Lamotte, James L. Palmer, Andrew Lloyd	0
18	1192 THE BURDEN OF VIRAL HEPATITIS C IN EUROPE: A PROPENSITY ANALYSIS OF PATIENT OUTCOMES 2011 ·Journal of Hepatology ·(unknown), Yuping Yuan, Jan-Samuel Wagner, G. LʼItalien, Phil McEwan, Paul C. Langley	1
19	The Cost-Effectiveness of Saxagliptin Versus NPH Insulin When Used in Combination with Other Oral Antidiabetes Agents in the Treatment of Type 2 Diabetes Mellitus in Poland 2011 ·Diabetes Technology & Therapeutics ·W Grzeszczak, Leszek Czupryniak, Katarzyna Kolasa, (unknown), (unknown), Phil McEwan	18
20	The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain 2009 ·European Journal of Cancer Care ·Rhys Pockett, Daniel Castellano, Phil McEwan, Alan Oglesby, BL Barber, Karen Chung	97

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact